FDA allows MabionCD20 as first-line therapy, trial shortened to 24 weeks

Oddifact SAS announces FDA consultation outcome permitting MabionCD20 as first-line therapy and shortening study duration to 24 weeks. This regulatory flexibility could accelerate development and market entry, but details on efficacy and safety remain undisclosed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works